Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma

Axel Hauschild, Ulrich Keilholz, John M. Kirkwood et al.|Journal of Clinical Oncology|2009

Cited by 545